Molecular Diagnostics Laboratories v. Hoffmann-La Roche Inc. et al.

I'll research this case using web search to verify the details.

Let me gather more details on the docket, settlement, and related litigation.

Let me verify additional details: the patents' technical content, the docket, and the remand outcome.

Case Overview and Background

Parties and their roles. Molecular Diagnostics Laboratories v. Hoffmann-La Roche Inc., No. 04‑cv‑01649 (HHK) (D.D.C.), was not a patent infringement suit — it was a direct‑purchaser antitrust class action asserting a Walker Process claim (fraudulent procurement of a patent as a Sherman Act §2 monopolization violation). The plaintiff, Molecular Diagnostics Laboratories ("MDL"), was a small operating diagnostics laboratory that purchased Thermus aquaticus DNA polymerase ("Taq") directly from the defendants; it sued as class representative for a class of direct purchasers of Taq and PCR‑related products. Neither side is an NPE/PAE or a university. The defendants were two large operating companies: Hoffmann‑La Roche Inc., the U.S. affiliate of the Swiss pharma group (with Roche Molecular Systems as the relevant Taq patent owner/licensor), and Applera Corporation, which the court described as "the successor in whole or part to defendants PE Biosystems Group, PE Applied Biosystems, PE Corporation, and/or the Perkin‑Elmer Corporation" — Roche's long‑time licensee/partner in PCR instruments and Taq. Counsel of record for MDL was Michael Hausfeld and Brian A. Ratner of Cohen, Milstein, Hausfeld & Toll (Washington, D.C.); defendants were represented by Joanne M. Guerrera and John E. Scribner (Weil, Gotshal & Manges, D.C.) and David J. Lender (Weil Gotshal, New York) (per the reported opinion, 402 F. Supp. 2d 276; casemine/CourtListener reproductions).

The accused technology and the patents. The technology at issue is Taq DNA polymerase — the thermostable enzyme (derived from the bacterium Thermus aquaticus) that made the polymerase chain reaction ("PCR") practical — and related PCR products and reagents. MDL alleged that Roche and Applera dominated the U.S. Taq market by enforcing a fraudulently obtained patent, US 4,889,818 ("Purified Thermostable Enzyme," issued to Cetus in 1989; Gelfand/Stoffel), which claims a purified thermostable DNA polymerase isolated from T. aquaticus. That patent (the "'818 patent") is the heart of the case: it had already been held unenforceable for inequitable conduct in Hoffmann‑La Roche v. Promega (N.D. Cal. 1999), a finding largely upheld by the Federal Circuit, Hoffmann‑La Roche, Inc. v. Promega Corp., 323 F.3d 1354 (Fed. Cir. 2003) (Newman, J., dissenting), and reaffirmed on remand, 319 F. Supp. 2d 1011 (N.D. Cal. 2004). The other patent listed in the case metadata, US 4,683,195 ("Process for Amplifying, Detecting, and/or Cloning Nucleic Acid Sequences," issued 1987 to Cetus; Mullis et al.), is the foundational PCR process patent. In the D.D.C. opinion, the court noted that "Roche holds other patents related to the PCR process, among them Patents Nos. 4,683,195 and 4,683,202," and MDL's complaint wove the '818 and the PCR patents into tying and market‑allocation allegations (the '202 patent, and derivative unenforceability questions over the '195/'202, were litigated in the parallel Promega line of cases). The '818 patent is the one actually driving the monopolization theory; the '195 is best understood as a related PCR‑family patent named in the scheme/tying allegations rather than a separately asserted "infringement" patent.

Procedural posture, venue, and why it matters. The case was filed in the U.S. District Court for the District of Columbia and assigned to Judge Henry H. Kennedy, Jr. The D.C. venue fit a nationwide direct‑purchaser class action and leveraged D.C.‑based plaintiff's antitrust counsel; it was not a plaintiff‑chosen "patent venue" case in the TC Heartland sense. Timing caveat: the case metadata states filed 2003‑09‑23, but the opinion itself states "MDL's complaint was filed on September 23, 2004," and the docket number (04‑cv‑01649) and the four‑year damages cutoff (purchases from September 23, 2000) are consistent with 2004 — so the 2003 date in the metadata appears to be off by one year (I could not independently confirm a 2003 filing). In its December 1, 2005 opinion, the court denied defendants' motions to dismiss in their entirety (with only a minor limitations carve‑back), holding that direct purchasers have standing to bring Walker Process claims — a notable extension, since such claims are overwhelmingly raised by competitors or targets of patent enforcement. Molecular Diagnostics Labs. v. Hoffmann‑La Roche, Inc., 402 F. Supp. 2d 276, 282 (D.D.C. 2005). After amendment of the class definition (direct purchasers from Sept. 23, 2000 forward) and defense summary‑judgment motions in 2008, the parties settled on September 26, 2008 for $33 million, with final approval by Judge Kennedy on December 19, 2008 (reported by Law360 as final approval on December 30, 2008); plaintiffs' counsel received roughly $11 million in fees plus over $3 million in costs, and MDL an incentive award (class notice and approval documents; UBalt law‑review case study). The case is notable as an early and influential direct‑purchaser Walker Process precedent, as epilogue to the Roche/Promega Taq inequitable‑conduct saga that invalidated one of the foundational biotech patents (Cetus sold the Taq/PCR assets to Roche for ~$300 million), and as a driver of Taq/PCR pricing and licensing scrutiny (Taq was reportedly the most‑purchased reagent under NIH grants). There is no IPR/PTAB linkage — the America Invents Act inter partes review regime began in 2012, well after these 1987/1989 patents expired and after this case closed; the relevant parallel proceeding is the Hoffmann‑La Roche v. Promega litigation (N.D. Cal. / Fed. Cir.), not an IPR.

Sourcing note: Party names, court, case number and patents are taken from the case metadata; substantive rulings are grounded in the 2005 opinion (402 F. Supp. 2d 276; CourtListener/casemine), the Federal Circuit's Promega decision (323 F.3d 1354), the D.D.C. class‑settlement notice and Law360's approval report, and a University of Baltimore law‑review case study. Post‑2008 corporate lineage for Applera/Applied Biosystems (e.g., its later combination into Life Technologies) is general industry context I did not verify in this search.

I'll research the docket-level chronology, the 2008 summary-judgment phase, settlement approval, and any appeal or parallel proceedings.

Key Legal Developments & Outcome — Chronological

Framing note (not a repeat): Because this was a Walker Process antitrust class action rather than an infringement suit, several of the categories you asked about — Markman/claim construction, infringement trial, JMOL/new-trial motions, IPR stays and PTAB proceedings — have no counterpart in this record. I flag each where it applies rather than inventing an event.

---

1. Filing and initial pleadings

No motion to transfer, no MDL Panel consolidation, and no stay motion appear in any source I reviewed.

2. Pre‑trial motions of substance

2005-12-01 — Motions to dismiss denied in their entirety (one carve‑back). Both defendants moved separately under 12(b)(6) and 9(b) on four grounds: (i) a direct purchaser lacks standing to bring a Walker Process claim (relying on In re Remeron, 335 F. Supp. 2d 522 (D.N.J. 2004), and Carrot Components); (ii) statute of limitations/tolling; (iii) failure to plead a conspiracy; (iv) Rule 9(b) particularity as to Applera's knowledge of the Cetus fraud. Judge Kennedy rejected each. Molecular Diagnostics Labs. v. Hoffmann‑La Roche, Inc., 402 F. Supp. 2d 276 (D.D.C. 2005) (2005 WL 3220218; 2005 U.S. Dist. LEXIS 30142). The only relief granted was temporal: MDL could pursue damages only for purchases after 2000‑09‑23, because the court held MDL was on notice of the inequitable conduct from the N.D. Cal.'s 1999‑12‑07 Roche I ruling, but applied a continuing‑violation theory under which each overcharge payment starts a new accrual — a purchaser‑specific holding the court expressly tied to its standing ruling. 402 F. Supp. 2d at 285–86.

Two sourcing caveats: (a) one secondary summary (UBalt fn. 36–41) recites the limitations trigger correctly as 1999‑12‑07 but a paraphrase in a Biotechnology Law Report piece garbles it as "December 7, 2003" — the 1999 date is the correct one; (b) the court itself noted that, apart from Remeron and Carrot, "neither the parties nor the court have been able to identify an instance in which a customer litigated a Walker Process claim," confirming this was a first‑impression ruling.

No motion to dismiss on the pleadings, no motion to strike, no 1292(b) certification, and no interlocutory appeal appear in the record I could verify — a notable point, since contemporaneous commentary predicted the standing holding "may be tested on appeal" (LexBlog, 2006-01-07). It never was.

3. Amended pleadings and class definition

• 2006-06-29 — Revised First Amended Complaint filed, repleading the class as direct purchasers of Taq products from 2000‑09‑23 to the present (UBalt case study, citing Revised First Am. Compl. ¶ 8, June 29, 2006). This is the operative pleading that carried the case to settlement.
• Class certification: I found no reported or docket‑confirmed contested certification opinion. What the record shows is a settlement class certified in connection with final approval, with the class period ultimately running 2000‑09‑23 through 2008‑08‑31 (Settlement Notice, Claim Period). I could not verify whether MDL filed a contested Rule 23(b)(3) motion before settling — an open item.

4. Discovery milestones of strategic significance

Verified specifics are thin, but three data points are meaningful:

• Damages/expert work drove the settlement architecture. The Notice describes a pro rata Plan of Distribution using a court‑approved damages expert's overcharge estimates across three product groups (A, B, C) — i.e., the plaintiffs' economic expert's overcharge model became the allocation formula. (Settlement Notice § F.)
• The claim period was cut at 2008‑08‑31, several weeks before the settlement execution date, indicating negotiated data cut‑offs for transactional purchase data.
• The conspiracy proof burden was framed around documents in defendants' control — the 2005 opinion expressly relied on the principle that dismissal is disfavored where "the proof is largely in the hands of the alleged conspirators" (quoting Hospital Corp. of America), which forecast a document‑heavy Roche/Applera licensing and patent‑prosecution discovery fight.

I could not verify specific deposition dates, document‑production volumes, or discovery‑motion rulings; PACER/RECAP docket text for this 2004 case was not retrievable in this search.

5. Summary judgment phase (2008) — never decided

• 2008 — Defendants filed motions for summary judgment (UBalt case study, citing "Applied Biosystems Inc.'s Memorandum of Points and Authorities in Support of Its Motion for Summary Judgment, No. 04‑CV‑01649"). The court never ruled on them; the case settled first. I could not confirm the filing dates or the specific grounds, though the natural targets were the Walker Process fraud element, antitrust injury/causation, and class issues.
• No Daubert ruling, no summary‑judgment opinion, and no Rule 56(d) stay are reflected in any source located.

6. Claim construction / trial / verdict / post‑trial motions

• Markman: none — no patent claim is construed in an antitrust overcharge case, and the '818 patent's unenforceability had already been adjudicated in N.D. Cal. (Hoffmann‑La Roche v. Promega, 319 F. Supp. 2d 1011 (N.D. Cal. 2004), following remand from 323 F.3d 1354 (Fed. Cir. 2003)).
• Trial: none. No verdict, no JMOL, no new‑trial motion. The case terminated by settlement before any trial date.

7. Settlement, judgment, and final disposition

Contradiction to flag: the prior section notes Law360 reporting final approval on 2008‑12‑30. The firm announcement (BSF, dated 2008‑12‑19) and the UBAlt case study both place approval on 2008‑12‑19; 2008‑12‑30 is most likely the date of the Law360 write‑up or the entry of the separate dismissal judgment. Prefer 2008‑12‑19 for the approval order, with the dismissal judgment date unconfirmed.

8. Parallel PTAB/IPR proceedings

None, and none possible. The '818 and '195 patents issued in 1989 and 1987 and expired well before the AIA's inter partes review regime took effect on 2012‑09‑16; there is no PTAB docket, no IPR/PGR/CBM, and therefore no stay posture. The functionally parallel proceedings were:

• Hoffmann‑La Roche, Inc. v. Promega Corp., N.D. Cal. (1992 filing; inequitable‑conduct holding 1999‑12‑07; 323 F.3d 1354 (Fed. Cir. 2003); remand judgment 319 F. Supp. 2d 1011 (N.D. Cal. 2004)) — the merits predicate for the Walker Process claim.
• The Roche/Applera PCR licensing-and-instrument relationship itself, which supplied the conspiracy allegations.

9. Subsequent treatment of the key ruling (worth noting for the "outcome")

The 2005 standing holding was influential but not uniformly followed. In a later opinion reproduced on CourtListener (Harvard deposition copy), a district court expressly found In re Remeron and In re Ciprofloxacin "more persuasive than the holding of Molecular Diagnostics" and dismissed direct‑purchaser Walker Process claims for lack of standing, warning against letting purchasers "dress[] their patent challenge with a Walker Process claim." I could not confirm that court's name or citation from the retrieved excerpt and would not attribute it without a verified cite.

---

Verification gaps to close if you want a docket‑grade chronology

1. Exact answer/counterclaim filing dates and any Rule 12(b) motion filing dates (pre‑2005‑12‑01).
2. Whether a contested Rule 23 motion was filed in 2006–2007, and the date of the settlement‑class certification.
3. The 2008 summary‑judgment filing dates and grounds (Dkt. nos. referenced in the UBAlt footnote but not reproduced).
4. The dismissal judgment docket entry versus the 2008‑12‑19 approval order (to resolve the 12‑19 vs. 12‑30 discrepancy

I'll research plaintiff's counsel of record, building on the Hausfeld/Ratner identification already in the case summary and verifying against docket sources.

Now let me pull the settlement notice and approval papers for the full signature block and any additional plaintiff firms, plus check for a CourtListener docket.

Important lead: Boies Schiller also reports serving as co-lead counsel. Let me verify that and identify which BSF attorneys appeared.

Plaintiff's Counsel of Record — Molecular Diagnostics Laboratories v. Hoffmann‑La Roche Inc., No. 04‑cv‑01649 (HHK) (D.D.C.)

Threshold correction on the question framing: this was not a patent infringement case. It was a direct‑purchaser antitrust class action asserting a Walker Process monopolization claim (Sherman Act § 2) premised on Roche's allegedly fraudulent procurement and enforcement of US 4,889,818; US 4,683,195 was a related PCR‑family patent named in the tying/scheme allegations (see the case‑overview section above). Counsel below are therefore antitrust/class‑action counsel, not patent‑infringement defense or prosecution counsel, though the case turned almost entirely on patent issues (inequitable conduct before the PTO, patent misuse, and the Roche v. Promega record).

Attorneys identified as appearing for the plaintiff

Both names appear in the counsel listing of the court's December 1, 2005 memorandum opinion — "Michael Hausfeld, Brian A. Ratner, Cohen, Milstein, Hausfeld [&] Toll, P.L.L.C., Washington, DC, for Plaintiff" — Molecular Diagnostics Labs. v. Hoffmann‑La Roche, Inc., 402 F. Supp. 2d 276 (D.D.C. 2005) (counsel block, as reproduced on Casemine/CourtListener), and both are the addressees for class counsel correspondence in the October 10, 2008 class settlement notice (Hausfeld first, Ratner as the alternative contact).

The second co‑lead firm — Boies Schiller (individual attorney not confirmed)

Boies, Schiller & Flexner LLP (now Boies Schiller Flexner LLP) publicly states that it "served as co‑lead counsel for the Class Plaintiffs" in this matter, and its December 19, 2008 announcement ties that role to the $33 million settlement receiving final approval that month (bsfllp.com, "BSF Achieves $33 Million Settlement on Behalf of Class in Antitrust and Patent Case Concerning DNA Amplification," Dec. 19, 2008). That is a firm‑level, self‑reported description, and it is consistent with the settlement notice's reference to "Class Plaintiffs' Co‑Lead Counsel" in the plural.

However, I could not identify the individual BSF attorney(s) who entered an appearance. BSF's name does not appear in the 2005 opinion's counsel block, and the class notice's designated contacts are the two Cohen Milstein attorneys. So BSF may have been added later (e.g., for the 2008 summary‑judgment phase) or may have acted in a supporting/co‑counsel capacity not reflected in the reported opinions. I am not naming a BSF partner here because I have no docket or filing evidence of a specific appearance, and inventing one would be exactly the kind of error to avoid.

Coverage and sourcing limitations (please read)

• No PACER docket sheet was retrieved. The attorney identification above rests on (a) the counsel block of the reported 2005 opinion, (b) the court‑approved class settlement notice (completeclaimsolutions.com/taq, PDF), (c) the BSF firm announcement, and (d) Ratner's Hausfeld LLP biography. A full D.D.C. docket pull (04‑cv‑01649) would likely show additional appearances by Cohen Milstein associates and possibly a BSF attorney of record; I cannot supply those names without the docket, and I have not guessed at them.
• No in‑house counsel identified. Nothing in the sources shows a Molecular Diagnostics Laboratories in‑house lawyer entering an appearance; the named plaintiff appears to have litigated entirely through outside class counsel. It also received a $40,000 incentive award for serving as named plaintiff.
• No local‑counsel split. Because Cohen Milstein's Washington, D.C. office housed both lead attorneys, the D.D.C. local‑rule function was effectively satisfied in‑house by the lead firm rather than by separate local counsel — a structural difference from the typical out‑of‑town‑lead‑plus‑local‑counsel arrangement.
• Firm‑name chronology matters for searching. The firm was "Cohen, Milstein, Hausfeld & Toll, P.L.L.C." during the litigation; after Hausfeld's 2008 departure it became Cohen Milstein Sellers & Toll PLLC, while Hausfeld LLP issued the November 2009 press release announcing distribution of the Taq settlement funds ("Hausfeld LLP Announces Distribution of Settlement Funds in Taq Antitrust Case," Nov. 20, 2009). Some databases render the name without the ampersand ("Cohen, Milstein, Hausfeld Toll, P.L.L.C."), which affects search recall.
• Date inconsistency to keep in mind. The case metadata's 2003‑09‑23 filing date conflicts with the opinion's statement that "MDL's complaint was filed on September 23, 2004," the 04‑cv‑01649 docket number, and the four‑year damages cutoff of September 23, 2000 — the 2004 date is correct, as flagged in the overview section. This matters for counsel research only in that any 2003‑dated appearances would belong to a different (nonexistent) filing.

Defense counsel (for contrast, already sourced in the overview)

Weil, Gotshal & Manges LLP — Joanne M. Guerrera and John E. Scribner (Washington, D.C.) and David J. Lender (New York) — for Roche and Applera.

I'll research the defense-side counsel of record from docket records, opinions, and firm/Law360 sources.

Let me dig into the docket and counsel listings, including Law360's docket-based attorney page and CourtListener's docket.

Correction to the task framing (flagged)

The request describes this as a "patent infringement case," but no infringement claim was ever asserted here. Molecular Diagnostics Laboratories v. Hoffmann‑La Roche Inc., No. 04‑01649 (HHK) (D.D.C.), was a direct‑purchaser antitrust class action asserting Walker Process fraud and § 1/§ 2 claims over the Taq polymerase patent (US 4,889,818) and related PCR patents — Law360's docket entry classifies it under NOS 410 (Antitrust), not 830 (Patent). So there is no conventional "patent infringement defense team" (no invalidity/non‑infringement counsel of record); the appearances are antitrust litigators. This is consistent with the case overview already generated and with the metadata's own "settled" status.

Counsel of record for Defendants

The two authoritative listings I could locate are (1) the attorney block of the court's December 1, 2005 opinion, 402 F. Supp. 2d 276, 279, and (2) the court‑approved class settlement notice dated October 10, 2008, which lists the defense‑side contact addresses for objections/communications.

Structural read

• Weil, Gotshal & Manges was the joint defense team for both Hoffmann‑La Roche and Applera on the pleadings stage — the 2005 opinion refers to "Applera and Roche each mov[ing] to dismiss" while the caption lists a single Weil block "for Defendants." Lender (NY) led, with Guerrera and Scribner as the D.C.‑anchored counsel of record.
• Arnold & Porter appears to have been Roche‑side counsel (Varma's own bio ties him to Roche Molecular Systems in exactly this case), and it surfaces in the record only at the 2008 settlement‑notice stage, not in the 2005 opinion.
• No in‑house counsel (Roche or Applera legal department) is identified in any source I found; corporate defendants in this era typically did not enter appearances in D.D.C. antitrust class actions.

Sourcing caveats (important)

• I could not pull the PACER docket sheet for No. 04‑cv‑01649 (paywalled), so I cannot state the full appearance list, entry dates, or any withdrawals/substitutions across 2004–2008. The 2005 opinion caption and the 2008 settlement notice are the two verifiable snapshots; attorneys who appeared only in intervening filings may be missing.
• Nothing indicates sealing of the appearances or of the settlement papers — the settlement notice, proof of claim, and opt‑out/objection procedures were publicly posted by the claims administrator (completeclaimsolutions.com/taq), and the opinion is published at 402 F. Supp. 2d 276.
• Firm office locations for Guerrera/Scribner (D.C.) and Lender (New York) are taken from the face of the reported opinion's attorney block; Arnold & Porter's address is from the 2008 settlement notice.
• On the filing‑date discrepancy already flagged in the case overview: Law360's docket-derived entry also shows September 23, 2004, corroborating 2004 rather than the metadata's 2003‑09‑23.